Çok Yüksek HbA1c Değerlerinin Diyabetik Komplikasyonlarla İlişkisinin Değerlendirilmesi

Yıl 2025, Cilt: 52 Sayı: 1, 171 - 176, 14.03.2025

Zuhat Urakçı , Alparslan Kemal Tuzcu , Zafer Pekkolay

https://doi.org/10.5798/dicletip.1657582

Öz

Amaç: Bu çalışmada çok yüksek HbA1c değerlerinin diyabetik komplikasyonlarla ilişkisini incelemeyi amaçladık.
Yöntemler: Ocak 2008 ve Haziran 2009 tarihleri arasında Dicle Üniversitesi Tıp Fakültesi Endokrinoloji Kliniği’nde diyabetes mellitus tanısı ile takip edilen, HbA1c değeri %12 ve üzerinde olan 80 hasta (50 tip 2 DM ve 30 tip 1 DM) ile HbA1c değeri %7 ve altında olan 80 hasta (50 tip 2 DM ve 30 tip1 DM) diyabetin komplikasyonları açısından karşılaştırıldı.
Bulgular: HbA1c değeri %12 ve üzerinde olan hastalarda retinopati, duyusal nöropati, motor nöropati ve otonom nöropati HbA1c değeri %7 ve altında olan hastalara göre daha yüksek bulundu (p<0.01). Çok yüksek HbA1c değeri olan hastalarda mikroalbüminüri ve makroalbüminüri daha yüksek oranda bulundu (p<0.01). Düzeltilmiş QT aralığı süresinde uzama (>420 msn) çok yüksek HbA1c değerleri olan hastalarda anlamlı olarak daha yüksek saptandı (p<0.01).
Sonuç: Kesitsel olarak bakılan çok yüksek HbA1c değerleri diyabetin komplikasyonları ile ilişkili bulundu. Üç aylık ortalama kan şekerinin takibinde önemli olan HbA1c diyabetin uzun dönem komplikasyonlarının izlemi açısından da önemli bir parametredir.

Anahtar Kelimeler

Diyabetes mellitus, HbA1c, komplikasyon.

Kaynakça

• 1.Timar B, Albai O. The Relationship BetweenHemoglobin A1c and Chronic Complications In DiabetesMellitus. Rom J Diabetes Nutr Metab Dis. 2012; 19(2):115-22.
• 2.Standards of medical care in diabetes. Diabetes Care.2016; 39(Suppl. 1): S4-S5.
• 3.Powers AC, Stafford JM, Rickels MR. Diabetes Mellitus:Complications. Harrison’s Principles of Internal Medicine.20th ed. New York: McGraw-Hill, 2019; Chapter 398:p.2875.
• 4.American Diabetes Association Professional PracticeCommittee. 11. Chronic kidney disease and riskmanagement: Standards of Care in Diabetes—2025.Diabetes Care. 2025; 48(Suppl. 1): S239–S51.
• 5.Kapa M, Koryciarz I, Kustosik N, Jurowski P,Pniakowska Z. Future Directions in Diabetic RetinopathyTreatment: Stem Cell Therapy, Nanotechnology, andPPARα Modulation. J.Clin. Med. 2025; 14(3): 683.
• 6.Zilliox LA. Diabetes and Peripheral Nerve Disease. ClinGeriatr Med. 2021; 37: 253–67.
• 7.Dal Canto E, Ceriello A , Rydén L, et al. Diabetes as acardiovascular risk factor: An overview of global trends ofmacro and micro vascular complications. Eur J PrevCardiol. 2019; 26(2_suppl): 25-32.
• 8.American Diabetes Association. 6. Glycemic Targets:Standards of Medical Care in Diabetes-2021. DiabetesCare. 2021; 44(Suppl. 1): S73-S84.
• 9.Gorst C, Kwok CS, Aslam S, et al. Long-term GlycemicVariability and Risk of Adverse Outcomes: A SystematicReview and Meta-analysis. Diabetes Care. 2015; 38(12):2354–69.
• 10.S. Zoungas, J. Chalmers, T. Ninomiya, et al. Associationof HbA1c levels with vascular complications and death inpatients with type 2 diabetes: evidence of glycaemicthresholds. Diabetologia. 2012; 55: 636–43.
• 11.American Diabetes Association: Screening fordiabetes. Diabetes Care. 2002; 25(Suppl.1): S21-S24.
• 12.Sartore G, Ragazzi E, Caprino R, Lapolla A. Long-termHbA1c variability and macro/microvascular complications in type 2 diabetes mellitus: a meta-analysis update. Acta Diabetologica. 2023; 60: 721–38.
• 13.Vivekanand, Ray S, Kumar S, Choudhury SP, BanerjeeA. Awareness about Hba1c - in Diabetics with and withoutretinopathy. South Eastern European Journal of PublicHealth. 2025; 1184–90.
• 14.American Diabetes Association: Tests of glycemia indiabetes. Diabetes Care. 2003; 26(Suppl. 1): S106-8.
• 15.Krolewski AS, Laffel LM, Krolewski M, Quinn M,Warram JH. Glycosylated hemoglobin and the risk ofmicroalbuminuria in patients with insulin-dependentdiabetes mellitus. N Engl J Med. 1995; 332: 1251-5.
• 16.Hanssen KF. Blood glucose control and microvascularand macrovascular complications in diabetes. Diabetes.1997; 46(Suppl 2): S101-S103.
• 17.UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas orinsulin compared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS33). Lancet. 1998; 352: 837–53.
• 18.Rahman MO, Kumar S. A Study on Association ofHbA1c Levels and Severity of Diabetic Retinopathy in thePatients of Diabetes Mellitus. EJCM. 2025; 15(2): 163-9.
• 19.Ezcurra Ferrer EJ, Licea Puig M, Díaz Díaz O.Glycosylated hemoglobin as a prognostic index ofappearance of vasculer complications in diabetic patients.Rev Clin Esp. 1990; 187(3): 121-4.
• 20.Agardh E, Agardh CD, Koul S, Torffvit O. A four-yearfollow-up study on the incidence of diabetic retinopathyin older onset diabetes mellitus. Diabet Med. 1994; 11(3):273-8.
• 21.Alswaina N. Association Between HbA1c Levels andthe Severity of Diabetic Retinopathy. Cureus. 2024;16(12): e76395.
• 22.Segato T, Midena E, Grigoletto F, et al. Theepidemiology and prevalence of diabetic retinopathy inthe Veneto region of North east Italy. Venneto Group forDiabetic Retinopathy. Diabet Med. 1991; 8: S11-S16.
• 23.Chawla A, Chawla R, Jaggi S. Microvasular andmacrovascular complications in diabetes mellitus:Distinct or continuum?. Indian J Endocr Metab. 2016;20(4): 546-51.
• 24.Adler AI, Boyko EJ, Ahroni AJ, et al. Risk factors fordiabetic peripheral sensory neuropathy. Results of theSeattle prospective diabetic foot study. Diabetes Care.1997; 20(7): 1162-7.
• 25.American Diabetes Association Professional PracticeCommittee. Summary of revisions: Standards of Care inDiabetes—2025. Diabetes Care. 2025; 48(Suppl. 1): S6–S13.
• 26.Fein F, Scheuer J. Heart Disease in diabetes mellitus:theory and practice. 4th ed. New York, NY: ElsevierScience Inc. 1990: 812-23.
• 27.Aburisheh K, AlKheraiji MF, Alwalan SI, et al.Prevalence of QT prolongation and its risk factors inpatients with type 2 diabetes. BMC Endocrine Disord.2023; 23(1): 50.
• 28.Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes andCardiovasculer disease: A statement for health careprofessionals from American Heart Association.Circulation. 1999; 100(10): 1134-46.
• 29.Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovasculardisease in diabetes mellitus. Ann Intern Med. 2004;141(6): 421-31.
• 30.Stratton IM, Adler AI, Neil HA, et al. Association ofglycaemia with macrovascular and microvascularcomplications of type 2 diabetes (UKPDS 35): prospectiveobservational study. BMJ. 2000; 321: 405-12.
• 31.Nathan DM, Cleary PA, Backlund JY, et al. Intensivediabetes treatment and cardiovascular disease in patientswith type 1 diabetes. N Engl J Med. 2005; 353: 2643-53.
• 32.American Diabetes Association Professional PracticeCommittee. 10. Cardiovascular disease and riskmanagement: Standards of Care in Diabetes—2025.Diabetes Care. 2025; 48(Suppl. 1): S207–S238.
• 33.Baty M, Chimoriya R, James S, et al. Diabetes inPeripheral Artery Disease: Prevalence, Complications,and Polypharmacy. J. Clin. Med. 2025; 14(4): 1383.
• 34. Warraich HJ, Rana S. Dyslipidemia in diabetes mellitusand cardiovascular disease. CardiovascularEndocrinology. 2017; 6(1): 27-32.